SCHEMBL3759702

SCHEMBL3759702

CCOC(=O)C1CCN(c2nsc(Cl)n2)CC1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.53
ALDH1A1 P00352 4/20 0.49
LGMN Q99538 2/20 0.46
KMT2A Q03164 3/20 0.46
KDM4E B2RXH2 3/20 0.46
MEN1 O00255 2/20 0.46
LMNA P02545 1/20 0.46
NPC1 O15118 1/20 0.46
HSD17B10 Q99714 2/20 0.46
SMN1; SMN2 Q16637 1/20 0.45
MAPK1 P28482 1/20 0.45
NPSR1 Q6W5P4 1/20 0.45
RAB9A P51151 1/20 0.45
PTPN11 Q06124 1/20 0.44
CYP2C19 P33261 1/20 0.44
TSHR P16473 2/20 0.44
ALOX12 P18054 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL868893 0.82 ALDH1A1 (0.60) MAPTALDH1A1LGMNKMT2AKDM4E
SCHEMBL2264334 0.81 MAPT (0.57) MAPTALDH1A1LGMNKMT2AKDM4E
SCHEMBL1292653 0.80 MAPT (0.53) MAPTALDH1A1LGMNKMT2AKDM4E
SCHEMBL10055318 0.77 ALDH1A1 (0.55) MAPTALDH1A1LGMNKMT2AKDM4E
SCHEMBL10078816 0.77 KDM4E (0.60) MAPTALDH1A1LGMNKMT2AKDM4E
SCHEMBL2383228 0.75 MAPT (0.60) MAPTALDH1A1LGMNKMT2AKDM4E
SCHEMBL20267520 0.75 MAPT (0.57) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL195417 0.74 KDM4E (0.60) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL2265144 0.74 MAPK1 (0.54) MAPTALDH1A1KMT2AKDM4EMEN1
SCHEMBL20267596 0.74 PTPN11 (0.57) MAPTALDH1A1KMT2AKDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7851473-B2 Amide compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2010-12-14 US disclosed
US-20080312226-A1 Amide Compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-12-18 US disclosed
EP-1813606-A1 AMIDE COMPOUND Takeda Pharmaceutical Company Limited (JP) 2007-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312226-A1 Amide Compound FAAH, FAAH2, CNR2 MAPT 3805/4885ALDH1A1 353/4885LGMN 4782/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.